The French specialist pharma company Advicenne Pharma SA raised €27 million in an initial public offering (IPO) of its shares on the Paris Euronext exchange on 4 December to advance its pipeline of drugs for orphan renal and neurological diseases.
GW Pharmaceuticals Plc said it intends to issue $225 million worth of its shares on the US Nasdaq market subject to market conditions and investor appetite.
Siemens AG plans to list its healthcare imaging and diagnostics business, Siemens Healthineers, on the Frankfurt Stock Exchange during the first half of 2018, Europe’s largest industrial manufacturing company said on 29 November.
AstraZeneca Plc has entered into a partnership with the Chinese-government backed Future Industry Investment Fund (FIIF) to create a stand-alone, joint venture company called Dizal Pharmaceutical that will develop and commercialise new medicines in China.
What will it take to build an integrated capital market in Europe? This question engaged executives at a BioEurope conference in Berlin on 6 to 8 November. The answer was both short and sweet, and long and complex.
Crispr Therapeutics AG and its joint venture with Bayer AG called Casebia Therapeutics LLP have signed an exclusive collaboration agreement with CureVac AG to develop therapeutics that exploit both the new gene editing and messenger RNA (mRNA) technologies.
Switzerland-based NousCom AG, which is developing cancer vaccines, has completed a €42 million Series B financing round led by new investor Abingworth, along with 5AM Ventures. The funds will be used to advance two candidate neoantigen vaccines.
In just two weeks, European life science companies have tapped the global capital markets for more than $900 million, taking advantage of buoyant stock prices and a favourable global economy. Funds have been raised by clinical stage companies developing medical therapeutics and devices, as well as by one venture capital company, BioGeneration Ventures. BioGeneration specialises in seed funding for European start-ups.
Novartis has announced plans to begin a tender for all of the shares of Advanced Accelerator Applications (AAA) SA, a radiopharmaceutical company that has an approved product for the treatment of gastroenteropancreatic neuroendocrine tumours. The offer is valued at $3.9 billion.
Eli Lilly and Co has obtained the services of CureVac AG for the discovery and development of up to five cancer vaccines, all of which will make use of the German company’s messenger RNA (mRNA) technology to target tumour neoantigens and fight the cancers.